Paragraph 4 Amendment of the Prescription Only Medicines (Human Use) Order 1997I1
United Kingdom
F1After article 5(1) of the Prescription Only Medicines (Human Use) Order 1997 (exempt medicinal products) M1, F2insert—
“(1A)In paragraph (1) “marketing authorisation” means—
(a)in relation to medicinal products for sale or supply in Great Britain, a UKMA(GB) or UKMA(UK);
(b)in relation to medicinal products for sale or supply in Northern Ireland, a UKMA(NI) or UKMA(UK), an EU marketing authorisation or a parallel import licence.”
Annotations
Textual amendments
- F1
Words in Sch. 8 para. 4 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(a)(i)
- F2
Words in Sch. 8 para. 4 substituted (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 194(a)(ii)
Marginal citations
- M1
S.I. 1997/1830. Article 5(1) was amended by S.I. 2012/1916.
Commencement
- I1
Sch. 8 para. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1